يعرض 1 - 20 نتائج من 71 نتيجة بحث عن '"Eleonora Restuccia"', وقت الاستعلام: 0.71s تنقيح النتائج
  1. 1
  2. 2
    Academic Journal
  3. 3
  4. 4
    Academic Journal
  5. 5
  6. 6

    المساهمون: Institut Català de la Salut, [Pietrantonio F, Manca P, Raimondi A] Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Bellomo SE, Corso S] Department of Oncology, University of Turin, Turin, Italy. Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy. [Berrino E] Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy. Department of Medical Sciences, University of Turin, Turin, Italy. [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Uvic-UCC, IOB-Quiron, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  7. 7

    المساهمون: Institut Català de la Salut, [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, IOB-Quirón, Barcelona, Spain. [Hoff PM] IDOR, Hospital Vila Nova Star, Rede D’Or-Sao Luiz, Sao Paulo, Brazil. [Shen L] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Haidian District, Beijing, People’s Republic of China. [Ohtsu A] Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Hospital, Kashiwa, Japan. [Shah MA] Meyer Cancer Center at Weill Cornell Medical College, New York, NY, USA. [Siddiqui A] Product Development Oncology, Roche Products Limited, Welwyn Garden City, UK, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  8. 8
  9. 9

    المساهمون: Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

    المصدر: European Journal of Cancer, 166, 219-228. ELSEVIER SCI LTD
    2022, ' Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial ', European Journal of Cancer, vol. 166, pp. 219-228 . https://doi.org/10.1016/j.ejca.2022.01.031

    وصف الملف: application/pdf

  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19

    المصدر: Journal of Clinical Oncology. 39:1448-1457

  20. 20